Kura Oncology CEO Troy Wilson Buys 100,000 Shares

What Happened

• Troy Edward Wilson, President, CEO and a director of Kura Oncology (KURA), purchased 100,000 shares in an open-market transaction on August 24, 2026. The weighted-average purchase price was $12.39 per share for a total cost of $1,239,000. This was a purchase (acquisition), which many investors view as a potentially bullish signal since an insider added to their stake.

Key Details

• Transaction date: 2026-08-24 (reported filing date 2026-08-24)
• Transaction type/code: Open market purchase (P)
• Shares acquired: 100,000
• Price: Weighted-average $12.39; trades ranged from $11.47 to $12.85 (see footnote)
• Total value: $1,239,000
• Shares owned after transaction: Not disclosed in the provided filing excerpt
• Footnote: The purchase was executed in multiple trades at prices between $11.47 and $12.85; the $12.39 figure is the weighted average. The reporting person offered to provide full trade-level details on request to the SEC, issuer, or a security holder.
• Timeliness: Filed the same day as the transaction (no late-filing indication in the provided data)

Context

• This was a straightforward open-market purchase (not an option exercise, award, or gift). Purchases by executives can be more informative than sales because they represent insiders deploying personal capital into the company; however, filings do not state motivation. If you track insider activity, this purchase increases the CEO's direct economic exposure to KURA.